...

U.S. FDA experts narrowly recommend Merck's COVID-19 new drug molnupiravir

US Materials 1 December 2021 04:48 (UTC +04:00)
U.S. FDA experts narrowly recommend Merck's COVID-19 new drug molnupiravir

An expert committee on Tuesday voted to narrowly recommend that the U.S. Food and Drug Administration (FDA) authorize a COVID-19 pill from Merck for high-risk adults, the first in a new class of antiviral drugs that could work against a wide range of variants, including Omicron, Trend reports citing Xinhua.

The drug, known as molnupiravir, has shown efficacy to modestly reduce the risk of hospitalization and death, predominantly from the Delta, Mu and Gamma variants, reported The New York Times (NYT). Merck plans to study whether molnupiravir is effective against the Omicron variant that was discovered days ago.

The panel, known as the Antimicrobial Drugs Advisory Committee, voted 13 to 10 in support of the FDA granting its use to patients who are older or have medical conditions that make them vulnerable to severe illness. The pill could be authorized in the United States within days, and available by year's end.

Last week, the company said that a final analysis found the drug to be about 30 percent effective at reducing the risk of hospitalization and death in high-risk people, lower than the 50 percent efficacy first announced in October after a preliminary look at the data.

Tags:
Latest

Latest